Reaction
Joint Lock reporting signals
As of the last recalculation, Joint Lock appears in 2,809 FAERS reports alongside 37 co-occurring drug terms. The strongest observed disproportionality signal is TOFACITINIB CITRATE (PRR 10.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tofacitinib Citrate | 19 | 10.8 | 10.8 |
| Leflunomide | 120 | 8.8 | 8.8 |
| Hydroxychloroquine Sulfate | 101 | 8.5 | 8.5 |
| Hydroxychloroquine | 78 | 7.9 | 7.9 |
| Tofacitinib | 174 | 7.4 | 7.4 |
| Upadacitinib | 77 | 7.2 | 7.2 |
| Adalimumab | 550 | 6.9 | 6.9 |
| Tocilizumab | 99 | 6.6 | 6.6 |
| Etanercept | 432 | 6.1 | 6.1 |
| Methotrexate | 297 | 5.7 | 5.7 |
| Sulfasalazine | 57 | 5.5 | 5.5 |
| Dalfampridine | 52 | 5.5 | 5.5 |
| Methotrexate Sodium | 312 | 5.2 | 5.2 |
| Certolizumab Pegol | 78 | 5.0 | 5.0 |
| Infliximab | 141 | 5.0 | 5.0 |
| Abatacept | 76 | 4.2 | 4.2 |
| Linagliptin | 10 | 4.1 | 4.1 |
| Desoximetasone | 9 | 3.5 | 3.5 |
| Interferon Beta-1B | 8 | 3.1 | 3.1 |
| Secukinumab | 64 | 3.0 | 3.0 |
| Teriflunomide | 18 | 3.0 | 3.0 |
| Ofatumumab | 13 | 2.9 | 2.9 |
| Risankizumab-Rzaa | 30 | 2.7 | 2.7 |
| Golimumab | 31 | 2.7 | 2.7 |
| Interferon Beta-1A | 66 | 2.6 | 2.6 |
| Voclosporin | 3 | 2.6 | 2.6 |
| Sarilumab | 9 | 2.5 | 2.5 |
| Vismodegib | 3 | 2.5 | 2.5 |
| Teriparatide | 34 | 2.2 | 2.3 |
| Dimethyl Fumarate | 37 | 2.2 | 2.2 |
| Diroximel Fumarate | 3 | 1.9 | 1.9 |
| Glatiramer Acetate | 15 | 1.9 | 1.9 |
| Natalizumab | 45 | 1.8 | 1.8 |
| Emicizumab | 3 | 1.8 | 1.8 |
| Apremilast | 29 | 1.5 | 1.5 |
| Evolocumab | 32 | 1.5 | 1.5 |
| Salicylic Acid | 5 | 0.7 | 0.7 |